Psilocybin-Research.comSearchable psilocybin and psilocin bibliometrics.
Published

Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability.

There remain significant gaps in knowledge about best practices for facilitated psychedelic care and psychedelic-assisted therapy. To inform the development of service models that support safe and beneficial experiences, this qualitative study explored expert perspectives on current and ideal standards of care, including key practices (e.g., screening, adapting care to diverse contexts) and regulatory and research challenges that influence service delivery. Online focus groups (n = 8) were conducted with a purposive U.S. sample of people with psychedelic content knowledge expertise, including providers (psychiatrists, clinical psychologists, addiction medicine experts, and licensed/unlicensed practitioners) and harm reduction specialists. Transcripts were analyzed through Thematic Analysis team-based coding using a combined inductive-deductive approach within a semantic framework. Participants (N = 38, mean age 47 (SD = 10) years, 53 % women, 84 % white) had an average of 10 years of psychedelic service experience (SD = 11) across diverse settings, including festivals/events, service centers, and clinical, research, ceremonial, community and 'underground' contexts. Five key themes emerged: (1) 'Strengthening Safety through Credibility and Accountability'; (2) 'Advancing Culturally Responsive and Inclusive Psychedelic Care'; (3) 'Healing in Community: The Crucial Role of Ongoing Support and Integration'; (4) 'Ensuring Safe Psychedelic Use: Preparation, Screening, Vulnerability, and Medication Management'; and (5) 'Providing Informed Guidance and Navigating Legal and Informational Gray Areas.' Overall, results underscore the need for stronger provider accountability structures, culturally inclusive practices, accessible and integrated community support, robust safety and screening protocols, and clearer guidelines to help providers navigate legal complexities, ensure safety, and optimize outcomes across diverse populations.

Open source BibTeX RIS

Bibliographic context

Journal
The International journal on drug policy
Date
2025-12-31
Source
PubMed
DOI
10.1016/j.drugpo.2025.104938
PubMed
40803962

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising ApproachDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21Does psilocybin help with mental health conditions?Zenodo (CERN European Organization for Nuclear Research) · 2026-01-21Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s DiseaseGlobal Journal of Medical Research · 2025-06-27Improving Best Practice Indicators for Psilocybin Assisted Therapy Using a Mul-tiphase Mixed Methods Delphi StudyInternational Journal of Multiple Research Approaches · 2025-04-29Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentUniversity of Groningen research database (University of Groningen / Centre for Information Technology) · 2026-06-28Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.Clinical toxicology (Philadelphia, Pa.) · 2026-06-22Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic PotentialDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21Psilocybin-Assisted Therapy in the Management of Anxiety and Depression Among Cancer PatientsDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21